Active surveillance for recurrent low-grade non-muscle-invasive bladder cancer: Can we take any advantage from the COVID-19 crisis?

Figures & data

Table 1. Inclusion and exclusion criteria, as well as the follow-up protocol, in the Bladder Cancer Italian Active Surveillance (BIAS) project.

Inclusion criteria	Exclusion criteria	Follow-up
1. NMIBC with stage pTa (Grade 1–2) and pT1a (Grade 2; extending into the lamina propria, but above the level of the muscularis mucosa); 2. Single tumour size <10 mm; 3. Number of lesions ranging from one and five; 4. Absence of haematuria; 5. Presence of negative urine cytology; 6. Subscribed informed consent.	1. History of a High-grade carcinoma (Grade 3); 2. History of carcinoma in situ; 3. Positive cytology findings have to be excluded.	Urine cytology, together flexible cystoscopy every 3 months during the first year and every 6 months during the subsequent years